Our President and Managing Director, Ms. Jennifer Che, and Principal, Ms. Pauli Wong, have been invited by the HKUST, Office of Knowledge Transfer to be speakers at the IP seminar – ‘Bright Ideas, Strong Barriers: A Patenting Masterclass’ on June 26, 2024 (Wednesday) from 15:00-16:15 at the HKUST- Chow Tak Sin Lecture Theater G (LT-G).

The seminar will be divided into two parts and focus on the following topics:

1) IP Basics, Innovation Oversight and Tips: Patent 101 and Top IP Mistakes By Start-Ups & Entrepreneurs by Ms. Pauli Wong

2) MedTech & Healthcare Hurdles: IP Challenges for Innovations in the GBA and China by Ms. Jennifer Che

This seminar is designed to enhance the understanding and awareness on IP and its significance in the academic and research fields.



Our Past Events

Recommended Insights

China’s Newest Examination Guidelines: Post-Filing Supplemental Data for Compounds (Part I)

28 April 2021
Post-filing data in China has been a constant issue for many patent practitioners around the world. Examiners seem to require it often, and yet the rules regarding when it is acceptable have seemed much stricter than other jurisdictions worldwide. In fact, we tried to summarize the latest state of the law in an earlier blog […]

AI is magical but NOT magic! Be specific in your AI patents!

9 January 2025
What is the standard of sufficient disclosure for AI-related patents: A case study in China The rapid growth of AI patent applications present significant challenges to existing patent application and examination practices. One of them is satisfying the requirement for sufficient disclosure. The following case was featured in the 2023 CNIPA Compilation of Key Decisions […]

AI, Big Data, and Blockchain - CNIPA seeks public comment on draft patent examination guidelines

21 November 2019
Exciting new changes continue to happen with the Chinese Patent Office (CNIPA). On November 12, 2019, the CNIPA published a new set of amendments to Part II Chapter 9 of the Patent Examination Guidelines (“Draft”) and requested public comment by December 11, 2019. In summary, the new guidelines clarify how emerging technologies involving artificial intelligence, […]

Do Promotional Marketing Materials Constitute an “Offer for Sale” under Chinese Patent Law? Bayer IP GmbH v. Nanjing Hang Seng Pharmaceutical

12 December 2023
Bayer's blockbuster drug Rivaroxaban has seen its share of patent litigations in China, several of which are big enough to be listed as Top 10 IP cases or 50 Representative IP cases. We summarized an invalidation case back in 2020 where all of Bayer’s claims directed towards the compound were upheld. Recently, another Rivaroxaban case […]
Top crossarrow-right